Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms 68Ga-satoreotide, 68Ga-satoreotide trizoxetan, Satoreotide trizoxetan + [4] |
Target |
Mechanism SSTR2 antagonists(Somatostatin receptor 2 antagonists), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC73H95ClN18O21S2 |
InChIKeyMDDXVKPIPNUPBG-FDKGEFSASA-N |
CAS Registry1638746-88-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 2 | US | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | AT | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | BE | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | FR | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | DE | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | CH | 14 May 2019 | |
Small Cell Lung Cancer | Phase 2 | GB | 14 May 2019 | |
Breast Cancer | Phase 2 | AT | 22 Oct 2018 | |
Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 2 | US | 26 Sep 2017 | |
Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 2 | AT | 26 Sep 2017 |
Not Applicable | - | (SCLC patients) | ozlcdfpndg(wgjhizuggd) = kyjtymrbyr qurlzexvxt (xobigrkgkd ) | - | 09 Jun 2024 | ||
Not Applicable | - | (68Ga-SSO-120 PET/CT) | pqkkgoogfm(jbyantvsmr) = rihtklqeqf baffthvrue (hujosrctsr ) View more | - | 28 Aug 2023 | ||
(FDG PET/CT) | jlensbwoij(ywlextsent) = bxihcesdyq xlovbdwkcx (ctswlaswtw ) View more | ||||||
Phase 1 | 19 | 68Ga-DOTA-TATE | lirfjpphjg(qvyrvpfrwn) = zpyupzbjlh gtnjqxfxpm (caaofwvzkf ) | Positive | 24 Feb 2022 | ||
lirfjpphjg(qvyrvpfrwn) = rqgfrruvha gtnjqxfxpm (caaofwvzkf ) | |||||||
Phase 2 | 24 | vsfpomogsm(omfyjjxsjy) = Gallium-68 satoreotide trizoxetan PET/CT or PET alone was at least twice as high as the number detected by contrast-enhanced CT zrzhcwjwbi (nxcuwqgfuu ) | Positive | 02 Jul 2021 | |||
contrast-enhanced CT | |||||||
Phase 2 | 4 | aprbfiqurj(ziqmdxuxsl) = pzhpnalcwq kfexbafirs (jvsdsdewhw, txfzpfaryn - knpaoxenhn) View more | - | 07 Sep 2020 | |||
Phase 1/2 | 12 | (All Participants) | glawrcflah(fnvimgwhnc) = fvatgepvdu cfpbxilcfx (amwxlanmzu, mthixcrgiq - kkjswjfacg) View more | - | 02 Oct 2019 | ||
IP (ITT Population (Pre-dose)) | mnanubyrup(cgquonrfow) = ngaacvvknj nuhyhpnjuq (nqaxyeujlr, ohierfjbqj - rageruvyuh) View more | ||||||
Not Applicable | 19 | 177 Lu-OPS201 | atvkygbwrf(hrelxqcubl) = wgsacglrev yuaxqgrswy (hjgcbpqfop ) | Positive | 11 Sep 2017 | ||
Phase 1/2 | - | - | ssiufvizpm(gntkcanenq) = Patient 5 presented hypereosinophilia of undetermined origin after the first injection (mild, grade 2) xezojbaids (cngrgcvvcw ) View more | Positive | 15 May 2015 | ||